Business

FDA grants orphan drug status to potential treatment for hemophilia

Alnylam Pharmaceuticals Inc., a Cambridge company specializing in a gene-silencing technology known as RNAi, said Wednesday that the Food and Drug Administration has granted orphan-drug status to an experimental hemophilia B treatment.

Such a designation gives a company incentives to develop treatments for rare diseases that do not have mass-market potential. For now, Alnylam is calling its hemophilia drug candidate ALN-AT3.

Advertisement

In a statement, Saraswathy Nochur, a senior vice president, said, “We believe that our subcutaneously delivered RNAi therapeutic represents an innovative approach for the management of hemophilia and has great potential to make a meaningful impact in the treatment of this often debilitating bleeding disorder.”

Hemophilias are hereditary disorders caused by genetic deficiencies of blood-clotting factors, resulting in recurrent bleeds into joints, muscles, and major internal organs.

Chris Reidy can be reached at reidy@globe.com.
Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to Globe.com for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com